Cambridge, MA-based Dyax (NASDAQ: [[ticker:DYAX]]) and South San Francisco-based FivePrime Therapeutics said today they have agreed to collaborate on an effort to discover new antibody drugs. Dyax will use its phage display technology to help FivePrime identify the best antibody candidates aimed at multiple biological targets. Dyax will get undisclosed technology license fees, and support for research. Dyax is also eligible for milestone payments and royalties if FivePrime successfully develops any drugs using its technology.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
